Search Results - (Author, Cooperation:J. R. Ingram)
-
1Latest Papers from Table of Contents or Articles in PressStaff View
Publication Date: 2018-02-17Publisher: Wiley-BlackwellPrint ISSN: 0007-0963Electronic ISSN: 1365-2133Topics: MedicinePublished by: -
2Latest Papers from Table of Contents or Articles in PressS. K. Dougan ; J. Ashour ; R. A. Karssemeijer ; M. W. Popp ; A. M. Avalos ; M. Barisa ; A. F. Altenburg ; J. R. Ingram ; J. J. Cragnolini ; C. Guo ; F. W. Alt ; R. Jaenisch ; H. L. Ploegh
Nature Publishing Group (NPG)
Published 2013Staff ViewPublication Date: 2013-10-22Publisher: Nature Publishing Group (NPG)Print ISSN: 0028-0836Electronic ISSN: 1476-4687Topics: BiologyChemistry and PharmacologyMedicineNatural Sciences in GeneralPhysicsKeywords: Animals ; Antibodies/immunology/metabolism ; Antibody Specificity/immunology ; B-Lymphocytes/*immunology/pathology/secretion/*virology ; Cell Death ; Female ; Hemagglutinin Glycoproteins, Influenza Virus/immunology/metabolism ; Immunoglobulin G/immunology/metabolism ; Lung/cytology/immunology/secretion/virology ; Lymph Nodes/cytology/immunology ; Male ; Mice ; Mice, Inbred C57BL ; Molecular Sequence Data ; Neutralization Tests ; Nuclear Transfer Techniques ; Orthomyxoviridae/pathogenicity/*physiology ; Receptors, Antigen, B-Cell/*immunology/metabolism ; Virus ReplicationPublished by: -
3Latest Papers from Table of Contents or Articles in PressJ. S. Burg ; J. R. Ingram ; A. J. Venkatakrishnan ; K. M. Jude ; A. Dukkipati ; E. N. Feinberg ; A. Angelini ; D. Waghray ; R. O. Dror ; H. L. Ploegh ; K. C. Garcia
American Association for the Advancement of Science (AAAS)
Published 2015Staff ViewPublication Date: 2015-03-07Publisher: American Association for the Advancement of Science (AAAS)Print ISSN: 0036-8075Electronic ISSN: 1095-9203Topics: BiologyChemistry and PharmacologyComputer ScienceMedicineNatural Sciences in GeneralPhysicsKeywords: CCR5 Receptor Antagonists/chemistry ; Chemokine CX3CL1/*chemistry ; Crystallography, X-Ray ; Cyclohexanes/chemistry ; Humans ; Ligands ; Piperidines/chemistry ; Protein Binding ; Protein Structure, Secondary ; Protein Structure, Tertiary ; Receptors, CXCR4/antagonists & inhibitors ; Receptors, Chemokine/agonists/*chemistry ; Triazoles/chemistry ; Viral Proteins/agonists/*chemistryPublished by: -
4Articles: DFG German National LicensesIngram, J. R. ; Routledge, P. ; Rhodes, J. ; Marshall, R. W. ; Buss, D. C. ; Evans, B. K. ; Feyerabend, C. ; Thomas, G. A. O.
Oxford, UK : Blackwell Science Ltd
Published 2004Staff ViewISSN: 1365-2036Source: Blackwell Publishing Journal Backfiles 1879-2005Topics: MedicineNotes: Background : Transdermal nicotine is of value in active ulcerative colitis but causes adverse events because of systemic absorption. Nicotine enemas may give rise to fewer adverse events.Aim : To assess the pharmacokinetics of nicotine enemas in three doses.Methods : Thirteen volunteers, all non-smokers but three ex-smokers, were given enemas on separate occasions containing 3, 6 and 9 mg of nicotine, in ascending dose order. Adverse events were recorded and blood samples taken over 8 h for measurement of serum nicotine and cotinine.Results : Enemas were retained by most subjects. Eleven of 14 adverse events were ‘early’– 30–105 min after the enema, corresponding to maximum plasma nicotine concentrations; three events were later, 4–8 h after the enema and unrelated to the tmax. ‘Early’ adverse events occurred in eight subjects – six with 9 mg. The three highest plasma nicotine concentrations were with 9 mg and associated with headache, nausea and sweating. Only one had adverse events with 3 mg and withdrew from the study. Nicotine Cmax with 6 and 9 mg doses were respectively two and three times the value with 3 mg. Peak nicotine concentrations occurred 44–50 min after the enema.Conclusion : The 6 mg dose of nicotine probably represents the dose to use in clinical practice – for the highest therapeutic dose with a low risk of adverse events.Type of Medium: Electronic ResourceURL: